Cyberonics Tops, Hit by Charges - Analyst Blog
August 26 2011 - 11:48AM
Zacks
Cyberonics (CYBX) reported first quarter 2012
adjusted EPS of 28 cents, surpassing the Zacks Consensus Estimate
of 26 cents per share and 12% higher than the year-ago quarter’s
adjusted EPS. The results include pre-tax charges of $1.28 million
associated with the product withdrawal as announced on August,
2011.
During the quarter, Cyberonics reported revenues of $52.7
million, up 18% year over year and ahead of the Zacks Consensus
Estimate of $51 million. The year-over-year growth was based on
higher sales in the U.S (up 8% to $43.8 million) and a 34.8%
increase in international revenues to $8.9 million. At constant
exchange rate (CER), total sales increased 22% year over year.
Increased investment in the European market along with changes
in the organizational structure, which took place earlier this
year, enhanced the company’s performance in this region. The
company reported solid results in the US based on an increase in
new patients and replacement generators. Revenues from AspireHC
(Model 105) generator contributed around 9% of worldwide sales in
the reported quarter.
Earlier this month, Cyberonics discontinued shipment of two
models of its Aspire platform generators. The company has also
suspended enrollment in its E-36 clinical trial pending resolution
of this hardware related design issue. Its decision was based on
the realization that stimulation output current delivered to
patients can be less than the output current programmed by a
physician.
Cyberonics believes that the withdrawal of AspireHC and AspireSR
generators will be a set back for the company’s growth. However, it
remains hopeful about further improvement in product development
under this segment.
Gross margin for the quarter declined 100 basis points (bps) to
86.8% due to a 26.7% rise in cost of revenue. Operating margin
contracted 456 bps year over year to 25.2% due to higher selling,
general and administrative expenses (up 22.8%) and research and
development expenses (up 27.1%).
Cyberonics exited the quarter with $81.6 million in cash and
cash equivalents compared with $89.3 million reported in the
year-ago quarter. During the reported quarter, Cyberonics
repurchased approximately 500,000 shares, of which 346,000 shares
were repurchased since the Board authorized a program for buying an
additional 1 million shares on June 7, 2011.
Guidance
Cyberonics reaffirmed its outlook for fiscal 2012. The company
expects revenues and income from operations in the range of
$212–$215 million and $54–$57 million, respectively (the Zacks
Consensus Revenue Estimate for fiscal 2012 was $214 million).
Recommendation
Although Cyberonics witnessed an expansion in the top line
attributable to the company’s strong position in the US and
international epilepsy market, we remain concerned about several
headwinds including withdrawal of shipment of the AspireHC and
AspireSR generators. We are also concerned about the competitive
pressure in the neuromodulation market from players such as
Medtronic (MDT) and St. Jude
(STJ). Currently, we have a long-term Neutral recommendation on
Cyberonics.
CYBERONICS INC (CYBX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jul 2023 to Jul 2024